secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2024-11-21T23:59:59+00:00
Accession:  0001753926-24-001983
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chromocell renamed Channel Therapeutics, reincorporates in Nevada; pipeline milestones expected soon
--------------------------------------------------------------------------------

- Name change to Channel Therapeutics effective Nov 18, 2024; reincorporation in Nevada for lower taxes and strategic flexibility.
- Depot program for postoperative nerve blocks: sustained drug release over 96 hours in animals; efficacy results imminent.
- Eye pain program: drops well tolerated in animals; efficacy results in weeks, toxicology data late Q1 2025, Phase II in Q2 2025.
- Chronic pain program exploring program-specific financing; kickoff expected in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000175392624001983/0001753926-24-001983-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000175392624001983/g084575_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-001983

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer